Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin resistance and concurrent relative insulin deficiency and glucagon dysregulation underlie T2D pathophysiology.33–35”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alterations in these mechanisms lead to an increased fasting glucose production and impaired hepatic glucose uptake, contributing to the pathogenesis of type 2 diabetes (T2D) [1].”
From Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510790103 · Cited by 1,312
Brüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals
Altarejos, J. Y., & Montminy, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3072 · Cited by 1,040
(1922) · PubMed · Cited by 753
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Somatostatin: Hypothalamic Inhibitor of the Endocrine Pancreas
Koerker, D. J., Ruch, W., Chideckel, E., Palmer, J., Goodner, C. J., Ensinck, J., & Gale, C. C. (1974) · Science · doi:10.1126/science.184.4135.482 · Cited by 519
New Perspectives on the Microvasculature of the Islets of Langerhans in the Rat
Bonner-Weir, S., & Orci, L. (1982) · Diabetes · doi:10.2337/diab.31.10.883 · Cited by 499
Unique Arrangement of α- and β-Cells in Human Islets of Langerhans
Bosco, D., Armanet, M., Morel, P., Niclauss, N., Sgroi, A., Muller, Y. D., Giovannoni, L., Parnaud, G., & Berney, T. (2010) · Diabetes · doi:10.2337/db09-1177 · Cited by 450
Glucagon physiology and pathophysiology in the light of new advances
Unger, R. H. (1985) · Diabetologia · doi:10.1007/bf00281991 · Cited by 361
Self-citationGerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327
Self-citationLeptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327
Self-citationInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303
Self-citationGLUCAGON ANTIBODIES AND AN IMMUNOASSAY FOR GLUCAGON*
Unger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1961) · Journal of Clinical Investigation · doi:10.1172/jci104357 · Cited by 285
Self-citationThe Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272
Paracrinology of islets and the paracrinopathy of diabetes
Unger, R. H., & Orci, L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006639107 · Cited by 269
Self-citationGlucagon: molecular physiology, clinical and therapeutic implications
Lefèbvre, P. J., & Unger, R. H. (1972) · Medical Entomology and Zoology · Cited by 268
Self-citationGlucagon physiology and pathophysiology
Sherwood, L. M., Parris, E. E., & Unger, R. H. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108192850806 · Cited by 267
Self-citationKimball, C. P., & Murlin, J. R. (1923) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)85474-6 · Cited by 250
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
The Banting Memorial Lecture 1975: Diabetes and the Alpha Cell
Unger, R. H. (1976) · Diabetes · doi:10.2337/diab.25.2.136 · Cited by 234
Self-citationGlucagon: Role in the Hyperglycemia of Diabetes Mellitus
Dobbs, R., Sakurai, H., Sasaki, H., Faloona, G., Valverde, I., Baetens, D., Orci, L., & Unger, R. (1975) · Science · doi:10.1126/science.1089999 · Cited by 229
Self-citationThe Hormonal Control of Hepatic Gluconeogenesis
EXTON, J. H., MALLETTE, L. E., JEFFERSON, L. S., WONG, E. H. A., FRIEDMANN, N., MILLER, T. B., & PARK, C. R. (1970) · Proceedings of the 1969 Laurentian Hormone Conference · doi:10.1016/b978-0-12-571126-5.50014-5 · Cited by 222
Hyperglucagonemia in diabetic ketoacidosis
Müller, W. A., Faloona, G. R., & Unger, R. H. (1973) · The American Journal of Medicine · doi:10.1016/0002-9343(73)90083-1 · Cited by 220
Self-citationLeptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice
Fujikawa, T., Chuang, J.-C., Sakata, I., Ramadori, G., & Coppari, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008025107 · Cited by 220
Making insulin-deficient type 1 diabetic rodents thrive without insulin
Yu, X., Park, B.-H., Wang, M.-Y., Wang, Z. V., & Unger, R. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806993105 · Cited by 219
Self-citationEffect of glucagon on glucose production during insulin deficiency in the dog.
Cherrington, A. D., Lacy, W. W., & Chiasson, J. L. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109174 · Cited by 213
Self-citationPetersen, K. F., & Sullivan, J. T. (2001) · Diabetologia · doi:10.1007/s001250100006 · Cited by 209
Hyperglucagonemia and Its Suppression: Importance in the Metabolic Control of Diabetes
Raskin, P., & Unger, R. H. (1978) · New England Journal of Medicine · doi:10.1056/nejm197808312990901 · Cited by 196
Self-citationGlucagon Antibodies and Their Use for Immunoassay for Glucagon.
Unger, R. H., Eisentraut, A. M., McCall, M. S., Keller, S., Lanz, H. C., & Madison, L. L. (1959) · Experimental Biology and Medicine · doi:10.3181/00379727-102-25338 · Cited by 177
Self-citationLiljenquist, J. E., Mueller, G. L., Cherrington, A. D., Keller, U., Chiasson, J.-L., Perry, J. M., Lacy, W. W., & Rabinowitz, D. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108649 · Cited by 168
Self-citationPSYCHIATRIC INDICATIONS FOR THE TERMINATION OF PREGNANCY
(1971) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1971.tb87854.x · Cited by 164
Roden, M., Perseghin, G., Petersen, K. F., Hwang, J. H., Cline, G. W., Gerow, K., Rothman, D. L., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118460 · Cited by 157
Levetan, C., Want, L. L., Weyer, C., Strobel, S. A., Crean, J., Wang, Y., Maggs, D. G., Kolterman, O. G., Chandran, M., Mudaliar, S. R., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.1 · Cited by 156
Glucose Suppression of Glucagon Secretion
Le Marchand, S. J., & Piston, D. W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.069195 · Cited by 156
Is HbA1c Affected by Glycemic Instability?
Derr, R., Garrett, E., Stacy, G. A., & Saudek, C. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2728 · Cited by 152
Brand, C. L., Rolin, B., Jørgensen, P. N., Svendsen, I., Kristensen, J. S., & Holst, J. J. (1994) · Diabetologia · doi:10.1007/bf00400461 · Cited by 146
Cherrington, A. D., Williams, P. E., Shulman, G. I., & Lacy, W. W. (1981) · Diabetes · doi:10.2337/diab.30.3.180 · Cited by 142
Self-citationNew perspectives on the microvasculature of the islets of Langerhans in the rat
Bonner-Weir, S., & Orci, L. (1982) · Diabetes · doi:10.2337/diabetes.31.10.883 · Cited by 131
PANCREATECTOMISED MAN: A MODEL FOR DIABETES WITHOUT GLUCAGON
Barnes, A., & Bloom, S. R. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91339-8 · Cited by 130
Evidence for a catabolic role of glucagon during an amino acid load.
Charlton, M. R., Adey, D. B., & Nair, K. S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118782 · Cited by 128
Glucose Disposal during Insulinopenia in Somatostatin-Treated Dogs
Shulman, G. I., Liljenquist, J. E., Williams, P. E., Lacy, W. W., & Cherrington, A. D. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109150 · Cited by 126
Self-citationBiological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist
Unson, C. G., Gurzenda, E. M., & Merrifield, R. B. (1989) · Peptides · doi:10.1016/0196-9781(89)90010-7 · Cited by 126
Normal Glucagon Signaling and β-Cell Function After Near-Total α-Cell Ablation in Adult Mice
Thorel, F., Damond, N., Chera, S., Wiederkehr, A., Thorens, B., Meda, P., Wollheim, C. B., & Herrera, P. L. (2011) · Diabetes · doi:10.2337/db11-0876 · Cited by 119
Persistent Pancreatic Glucagon but not Insulin Response to Arginine in Pancreatectomized Dogs
MASHITER, K., HARDING, P. E., CHOU, M., MASHITER, G. D., STOUT, J., DIAMOND, D., & FIELD, J. B. (1975) · Endocrinology · doi:10.1210/endo-96-3-678 · Cited by 109
A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects
Qureshi, S. A., Rios Candelore, M., Xie, D., Yang, X., Tota, L. M., Ding, V. D.-H., Li, Z., Bansal, A., Miller, C., Cohen, S. M., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3267 · Cited by 109
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
Ali, S., Lamont, B. J., Charron, M. J., & Drucker, D. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43615 · Cited by 108
Nyholm, B., Ørskov, L., Hove, K. Y., Gravholt, C. H., Møller, N., George, K., Alberti, M. M., Moyses, C., Kolterman, O., & Schmitz, O. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90232-9 · Cited by 106
Magnusson, I., Rothman, D. L., Gerard, D. P., Katz, L. D., & Shulman, G. I. (1995) · Diabetes · doi:10.2337/diab.44.2.185 · Cited by 97
Localization of glucagon in the alpha cells in the pancreatic islet by immunofluorescent technics.
Baum, J., Simons, B. E., Unger, R. H., & Madison, L. L. (1962) · PubMed · Cited by 97
Self-citationBrand, C. L., Jørgensen, P. N., Svendsen, I., & Hoist, J. J. (1996) · Diabetes · doi:10.2337/diab.45.8.1076 · Cited by 94
Influence of Insulin in the Ventromedial Hypothalamus on Pancreatic Glucagon Secretion In Vivo
Paranjape, S. A., Chan, O., Zhu, W., Horblitt, A. M., McNay, E. C., Cresswell, J. A., Bogan, J. S., McCrimmon, R. J., & Sherwin, R. S. (2010) · Diabetes · doi:10.2337/db10-0014 · Cited by 94
The Effect of Insulin on the Alpha-Cell Response to Hyperglycemia in Long-Standing Alloxan Diabetes
Braaten, J. T., Faloona, G. R., & Unger, R. H. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107638 · Cited by 94
Self-citationCharacterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor
Cascieri, M. A., Koch, G. E., Ber, E., Sadowski, S. J., Louizides, D., de Laszlo, S. E., Hacker, C., Hagmann, W. K., MacCoss, M., Chicchi, G. G., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8694 · Cited by 92
Similar Dose Responsiveness of Hepatic Glycogenolysis and Gluconeogenesis to Glucagon In Vivo
Stevenson, R. W., Steiner, K. E., Davis, M. A., Hendrick, G. K., Williams, P. E., Lacy, W. W., Brown, L., Donahue, P., Lacy, D. B., & Cherrington, A. D. (1987) · Diabetes · doi:10.2337/diab.36.3.382 · Cited by 83
Self-citationThe Roles of Insulin, Glucagon, and Free Fatty Acids in the Regulation of Ketogenesis in Dogs
Keller, U., Chiasson, J.-L., Liljenquist, J. E., Cherrington, A. D., Jennings, A. S., & Crofford, O. B. (1977) · Diabetes · doi:10.2337/diab.26.11.1040 · Cited by 83
Self-citationYang, J., MacDougall, M. L., McDowell, M. T., Xi, L., Wei, R., Zavadoski, W. J., Molloy, M. P., Baker, J. D., Kuhn, M., Cabrera, O., et al. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-281 · Cited by 82
Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency.
Cherrington, A. D., LILJENQUIST, J. E., Shulman, G. I., Williams, P. E., & LACY, W. W. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.236.3.e263 · Cited by 77
Self-citationThe Amino Acid Sequence of Glucagon
BROMER, W. W., Sinn, L. G., Staub, A., & Behrens, O. K. (1957) · Diabetes · doi:10.2337/diab.6.3.234 · Cited by 77
Compartmental modeling of glucagon kinetics in the conscious dog
Dobbins, R. L., Davis, S. N., Neal, D. W., Cobelli, C., Jaspan, J., & Cherrington, A. D. (1995) · Metabolism · doi:10.1016/0026-0495(95)90051-9 · Cited by 72
Self-citationBuse, J. B., Weyer, C., & Maggs, D. G. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.3.137 · Cited by 71
Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes.
Parker, J. C., McPherson, R. K., Andrews, K. M., Levy, C. B., Dubins, J. S., Chin, J. E., Perry, P. V., Hulin, B., Perry, D. A., Inagaki, T., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2079 · Cited by 65
Gastric A-Cell Function in Insulin-Deprived Depancreatized Dogs1
BLAZQUEZ, E., MUNOZ-BARRAGAN, L., PATTON, G. S., ORCI, L., DOBBS, R. E., & UNGER, R. H. (1976) · Endocrinology · doi:10.1210/endo-99-5-1182 · Cited by 64
Self-citationInsulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan
Akram, J., Verga, V. D., & The Ramadan Study Group (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00164.x · Cited by 61
Foà, P. P., Weinstein, H. R., & Smith, J. A. (1949) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1949.157.2.197 · Cited by 61
Paranjape, S. A., Chan, O., Zhu, W., Horblitt, A. M., Grillo, C. A., Wilson, S., Reagan, L., & Sherwin, R. S. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00304.2011 · Cited by 52
Holste, L. C., Connolly, C. C., Moore, M. C., Neal, D. W., & Cherrington, A. D. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.3.e488 · Cited by 48
Self-citationGlucagon as a Critical Factor in the Pathology of Diabetes
Edgerton, D. S., & Cherrington, A. D. (2011) · Diabetes · doi:10.2337/db10-1594 · Cited by 47
Self-citationKalra, S. P. (2009) · Peptides · doi:10.1016/j.peptides.2009.07.021 · Cited by 46
Piper, H. A., Allen, R. S., & Murlin, J. R. (1923) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)85473-4 · Cited by 44
Rivera, N., Grueter, C. A., Edgerton, D. S., Rodewald, T., Neal, D. W., Nishimura, E., Larsen, M. O., Jacobsen, L. O., Kristensen, K., Brand, C. L., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.115717 · Cited by 43
Self-citationFRADKIN, J., SHAMOON, H., FELIG, P., & SHERWIN, R. S. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-4-698 · Cited by 43
Extrapancreatic Glucagon and Glucagonlike Immunoreactivity in Depancreatized Dogs
Muller, W. A., Girardier, L., Seydoux, J., Berger, M., Renold, A. E., & Vranic, M. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109096 · Cited by 39
Cherrington, A. D., Williams, P. E., Shulman, G. I., et al. (1981) · Diabetes · doi:10.2337/diabetes.30.3.180 · Cited by 39
Self-citationFurther Experimental Note on the Correlation of Action of Antagonistic Muscles
Sherrington, C. (1893) · BMJ · doi:10.1136/bmj.1.1693.1218 · Cited by 37
Control of hepatic glucose output by glucagon and insulin in the intact dog.
Cherrington, A. D., Chiasson, J. L., LILJENQUIST, J. E., LACY, W. W., & Park, C. R. (1978) · PubMed · Cited by 36
Self-citationMeier, J. J., Ueberberg, S., Korbas, S., & Schneider, S. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2010 · Cited by 35
Stevenson, R. W., Williams, P. E., & Cherrington, A. D. (1987) · Diabetologia · doi:10.1007/bf00275744 · Cited by 33
Self-citationα- and β-Cell Responses to Small Changes in Plasma Glucose in the Conscious Dog
Flattem, N. L., Igawa, K., Shiota, M., Emshwiller, M., Neal, D. W., & Cherrington, A. D. (2001) · Diabetes · doi:10.2337/diabetes.50.2.367 · Cited by 31
Self-citationNielsen, M. F., Wise, S., Dinneen, S. F., Schwenk, W. F., Basil, A., & Rizza, R. A. (1997) · Diabetes · doi:10.2337/diab.46.12.2007 · Cited by 30
Control of Glucose Production in vivo by Insulin and Glucagon
Cherrington, A. D. (2001) · Comprehensive Physiology · doi:10.1002/cphy.cp070225 · Cited by 29
Self-citationMEDICAL AND SURGICAL INTELLIGENCE.
NA (1823) · The Lancet · doi:10.1016/s0140-6736(01)18841-0 · Cited by 29
Magnusson, I., Rothman, D. L., Gerard, D. P., et al. (1995) · Diabetes · doi:10.2337/diabetes.44.2.185 · Cited by 29
Gastric A-cell function in normal dogs
Muñoz-Barragán, L., Blázquez, E., Patton, G. A., DOBBS, R. E., & Unger, R. (1976) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1976.231.4.1057 · Cited by 28
Self-citationLILJENQUIST, J. E., Bloomgarden, Z. T., Cherrington, A. D., Perry, J., & Rabin, D. U. (1979) · Diabetologia · doi:10.1007/bf01219739 · Cited by 27
Self-citationRegulation of hepatic glucose output by glucose in vivo
Müller, M. J., Möring, J., & Seitz, H. J. (1988) · Metabolism · doi:10.1016/0026-0495(88)90029-7 · Cited by 27
Ferner, H. (1953) · The American Journal of Digestive Diseases · doi:10.1007/bf02895538 · Cited by 27
Similar dose responsiveness of hepatic glycogenolysis and gluconeogenesis to glucagon in vivo
Stevenson, R. W., Steiner, K., Davis, M. A., et al. (1987) · Diabetes · doi:10.2337/diabetes.36.3.382 · Cited by 27
Ørskov, L., Nyholm, B., Hove, K. Y., Gravholt, C. H., Møller, N., & Schmitz, O. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00162.x · Cited by 25
Effect of glucagon on hepatic lactate metabolism in the conscious dog
Davis, M. A., Williams, P. E., & Cherrington, A. D. (1985) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1985.248.4.e463 · Cited by 25
Self-citationWada, M., Connolly, C. C., Tarumi, C., Neal, D. W., & Cherrington, A. D. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.268.2.e194 · Cited by 23
Self-citationRole of glucagon and insulin in control of glucose turnover
Cherrington, A. D., & Vranić, M. (1971) · Metabolism · doi:10.1016/0026-0495(71)90010-2 · Cited by 22
Self-citationBringer, J., Mirouze, J., Marchal, G., Pham, T. C., LUYCKX, A. S., Lefebvre, P., & Orsetti, A. (1981) · Diabetes · doi:10.2337/diab.30.10.851 · Cited by 20
USE OF GLUT‐4 NULL MICE TO STUDY SKELETAL MUSCLE GLUCOSE UPTAKE
Charron, M. J., Gorovits, N., Laidlaw, J., Ranalletta, M., & Katz, E. B. (2005) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2005.04189.x · Cited by 18
The Role of Glucagon Deficiency in the Houssay Phenomenon of Dogs
Nakabayashi, H., DOBBS, R. E., & Unger, R. H. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109053 · Cited by 17
Self-citationBrand, C. L., Jorgensen, P. N., Svendsen, I., et al. (1996) · Diabetes · doi:10.2337/diabetes.45.8.1076 · Cited by 17
Endocrine Cells in Oxyntic Mucosa of a Dog 5 Years after Pancreatectomy
Ravazzola, M., Baetens, D., Engerman, R. L., Kovacevic, N., Vranić, M., & Orci, L. (1977) · Hormone and Metabolic Research · doi:10.1055/s-0028-1093504 · Cited by 12
An important role for glucagon in the regulation of glucose production in vivo
LILJENQUIST, J. E., Chiasson, J. L., Cherrington, A. D., Keller, U., Jennings, A. S., Bomboy, J. D., & LACY, W. W. (1976) · Metabolism · doi:10.1016/s0026-0495(76)80144-8 · Cited by 11
Self-citationNielsen, M. F., Wise, S. D., Dinneen, S. F., et al. (1997) · Diabetes · doi:10.2337/diabetes.46.12.2007 · Cited by 9
Bringer, J., Mirouze, J., Marchal, G., et al. (1981) · Diabetes · doi:10.2337/diabetes.30.10.851 · Cited by 7
[Heterocellular coupling in cultures of endocrine pancreatic cells].
Meda, P., Kohen, E., Kohen, C., & Orci, L. (1981) · PubMed · Cited by 2
Research works printed but not linked: 10
- Banting, 1922, Can Med Assoc J., 12, 141
- Cherrington, 1978, Biochem Soc Symp., 43, 31
- Exton, 1970, Recent Prog Horm Res., 26, 411
- Cherrington, 1979, Am J Physiol., 236, E263
- Davis, 1985, Am J Physiol., 248, E463
- Wada, 1995, Am J Physiol., 268, E194
- Holste, 1997, Am J Physiol., 273, E488
- Baum, 1962, Diabetes., 11, 371
- Meda, 1981, C R Seances Acad Sci III., 293, 607
- Cherrinton AD. Control of glucose production in vivo by insulin and glucagon. In:Handbook of Physiology . Vol. 2. 2011:759–785. · DOI · Paper page
Cited by
Mechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
“In addition to insulin resistance, aberrant counterregu-latory hormone action in the liver also contributes to the progression of type 2 diabetes (264).”
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
“Leptin clearly has pleiotropic effects on glucose metabolism, including reduction in food intake, which reduces ectopic lipid accumulation and improves hepatic and muscle insulin action in lipodystrophic individuals (63); reduction of glucagon secretion (104); neural regulation of hepatic glucose production (105); and…”
BackgroundBiguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 833
Metabolic functions of FABPs—mechanisms and therapeutic implications
Hotamisligil, G. S., & Bernlohr, D. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.122 · Cited by 712
Metadata
- Authors
- Unger, R. H., & Cherrington, A. D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Unger, Roger H.
- ORCID
- Cherrington, Alan D.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-01-03
- Volume
- 122
- Issue
- 1
- Pages
- 4-12
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3248306
- OpenAlex
- W2113278846
- Cited by
- 670
- References
- 100
- Citations by year
- 2026: 30 · 2025: 28 · 2024: 38 · 2023: 41 · 2022: 36 · 2021: 46 · 2020: 45 · 2019: 48 · 2018: 68 · 2017: 54 · 2016: 49 · 2015: 56 · 2014: 57 · 2013: 48 · 2012: 26
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Amylin Pharmaceuticals
- University of Texas Southwestern Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, hyperglucagonemia, diabetes pathophysiology, insulin deficiency, hepatic glucose production, ketogenesis, leptin, somatostatin, glucagon receptor, pancreatic beta cells, alpha cells, anti-insulin serum
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Glucagon, Humans, Insulin, Liver, Pancreas, Glycogenolysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.